10.00-16.45

POSTGRADUATE COURSE ‘Liver disease for the general gastroenterologist’ – Hall 1

10.00-12.50

Chair : Professor AK Burroughs and Professor E Elias

10.00-10.30

When, how and which patient to treat with HBV infection (Dr D Mutimer, Birmingham)

10.30-11.00

When, how and which patient to treat with HCV infection (Professor G Foster, London)

11.00-11.30

Management of NAFLD; including – Does everyone need a liver biopsy? (Professor A-M Diehl, North Carolina)

11.30-11.50

Coffee

11.50-12.20

Fibrosis in the liver

(i)  Non invasive markers – Are they sufficient ? (Dr W Rosenberg, Southampton

12.20-12.50

Fibrosis in the liver

(ii)  Role of histology – Is it the gold standard?  Professor A Dhillon, London)

13.45-16.45

Chair : Dr J Freeman and Professor JC Atherton

13.45-14.15

Optimal management of acute liver failure; including – When to refer to a transplant centre (Dr J Wendon, London)

14.15-14.45

Optimal management of renal failure in cirrhosis; including – Can it recover without filtration/dialysis ? (Professor V Arroyo, Barcelona)

14.45-15.15

Drug induced liver disease; including – Can it be predicted? and how can the diagnosis be made? (Professor D Pessayre, Clichy)

15.15-15.45

Tea

15.45-16.15

Haematological and vascular complications affecting the liver; including – Role of anticoagulation (Professor D Valla, Clichy)

16.15-16.45

Imaging in liver and biliary disease in 2006; including – Algorithms for investigation of space occupying lesions, and What’s important for staging (Dr J Karani, London)

17.00-19.00

TRAINEES IN GASTROENTEROLOGY : ‘Training tomorrow’s consultant gastroenterologists’ : Hall 1 : Chair – Dr Robert Logan

Introduction (Dr Robert Logan, TIGs Academic Advisor)

Research (Professor David Rampton, Professor of Clinical Gastroenterology, Barts and The London)

Endoscopy (Dr Robin Teague, BSG Endoscopy Section)

What’s the ‘X’ factor in training a gastroenterologist (Dr Ian Forgacs, SAC in Gastroenterology)

19.00

Annual Business Meeting

08.30-12.30

SURGICAL SECTION IN ASSOCIATION WITH THE ASSOCIATION OF COLOPROCTOLOGY (ACPGBI) AND IBD SECTION : ‘Surgical Challenges in IBD’ : Hall 1

08.30-10.30

Chair : Mr A Shorthouse and Dr S Travis

08.30-09.00

Impact of biological therapy on surgery (Professor G van Assache, Leuven)

09.00-09.30

Long term consequences of ileo-anal pouches (Professor RJ Nicholls, London)

09.30-09.45

001

Clinical and molecular characteristics of isolated colonic Crohn's disease (CD). (Hancock L, Ahmad T, Warren BF, Mortensen NJ,

Jewell DP)

09.45-10.00

002

Analysis of CCL20 variants in IBD provides further evidence for genetic heterogeneity in disease susceptibility. (Lees CW, Nimmo ER,

Russell RK, van Limbergen J, Smith A, Drummond HE, Satsangi J)

10.00-10.30

Influence of cancer targets on IBD (Mr K Hosie, Plymouth)

10.30-11.00

Coffee

11.00-12.30

Chair : Mr P Finan and Dr S Bloom

11.00-11.15

National IBD Audit : Update 2006 (Dr K Leiper, Liverpool)

11.15-11.45

Infliximab, ciclosporin or colectomy for severe UC? (Dr S Travis, Oxford)

11.45-12.00

003

Intensive granulocyte and monocyte apheresis versus intravenous prednisolone in patients with severe ulcerative colitis: a multicentre randomized controlled study. (Saniabadi AR, Hanai H, Iida T,

Watanabe F, Yamada M, Takeuchi K, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K)

12.00-12.30

Preventing post-operative recurrence of Crohn’s (Dr H Steinhart, Toronto)

09.00-12.00

LIVER FREE PAPERS : Hall 5 : Chair – Dr J Freeman and Dr S Taylor-Robinson

09.00-09.15

004

Decompensated alcoholic liver disease (ALD): factors associated with early mortality; the effect of corticosteroids. (McFarlane E, Kerss J, Jones J, Skinner J, Gleeson D)

09.15-09.30

005

Hepatic inflammation increases portal pressure through inhibition of eNOS activity - potential mechanisms. (Mookerjee RP, Davies NA, Hodges SJ, Dalton RN, Williams R, Jalan R)

09.30-09.45

006

An assessment of  cardiovascular morbidity and mortality following orthotopic liver transplantation. (McAvoy NC, Ferguson JW, Hayes PC)

09.45-10.00

007

How good are we at minimising cardiovascular risk following orthotopic liver transplant? (Oliver DG, Agarwal K, Manas D, Hudson M)

10.00-10.15

008

Management of bleeding ectopic varices: the Edinburgh experience. (Kochar N, Tripathi D, McAvoy NC, Ireland H, Redhead DN, Hayes PC)

10.15-10.45

Coffee

10.45-11.00

009

Long term follow-up of endoscopic histoacryl injection for the management of gastric variceal bleeding. (Rajoriya N, Gray J, Gaya D, Reid G, Forrest EH, Morris AJ, MacKenzie JF, Carter RC, McKay CJ, Stuart R, Stanley AJ)

11.00-11.15

010

An audit of patients with liver biopsy proven alcoholic cirrhosis against Brithish Society of Gastroenterology (BSG) guidelines on screening for complications. (Gasem J, Eddib O, Gregory K, Smart Hl, Lombard MG, Gilmore IT)

11.15-11.30

011

Investigating the role of vascular endothelial growth factor (VEGF) signaling in cerebral edema due to experimental acute liver failure. (Aspinall RJ, Weis S, Barnes L, Cheresh DA, Pockros PJ)

11.30-11.45

012

Can erythropoietin treatment during antiviral drug treatment for Hepatitis C be cost effective? (Cash WJ, Patterson K, Callender ME,

McDougall NI)

11.45-12.00

013

PSC: Edinburgh liver transplant experience 1992-2005. (Din S, MacGilchrist A, Bathgate A)

12.00-12.30

SHEILA SHERLOCK LECTURE :

‘Fixing Fatty Livers’ – Dr Anna Mae Diehl

(introduced by Dr S Taylor-Robinson)

08.30-12.00

ENDOSCOPY FREE PAPERS AND FOUNDATION LECTURE : Hall 8 : Chair – Dr RH Teague and Dr JRB Green

08.30-08.45

014

Entonox is superior to intravenous sedation: proof from randomised controlled trial. (Maslekar S, Hughes M, Skinn E, Gardiner A, Culbert B, Duthie GS)

08.45-09.00

015

A prospective, randomized, comparison of adrenaline injection in combination with detachable snare versus adrenaline injection alone in the prevention of post-polypectomy bleeding in large colonic polyps. (Paspatis GA, Paraskeva K, Theodoropoulou A, Mathou N, Vardas E, Oustamanolakis P, Chlouverakis G, Karagiannis I)

09.00-09.30

ENDOSCOPY FOUNDATION LECTURE :

‘Therapeutic Endoscopy; evolution of a specialty’

Dr KR Palmer, Edinburgh

09.30-09.45

016

A comparison of midazolam plus fentanyl or pethidine as sedation for colonoscopy. (Hayee BH, Rowbotham DS, Saxena V, McNair A)

09.45-10.00

017

The BSG draft safety and quality indicators for colonoscopy: are they achievable? (Murray IA, Dalton HR)

10.00-10.15

018

Non-medical colonoscopists are safe and effective: resutls from randomised controlled trial. (Maslekar S, Hughes M, Skinn E,

Gardiner A, Culbert B, Duthie GS)

10.15-10.45

Coffee

10.45-11.00

019

The use of human thrombin for the treatment of gastric and ectopic varices. (McAvoy NC, Hayes PC)

11.00-11.15

020

Successful cannulation at ERCP - are we as good at it as we think we are? results of a large scale survey of endoscopic retrograde

cholangio-pancreatography. (Williams EJ, Steering Committee, BSG Audit of ERCP)

11.15-11.30

021

Preliminary results of a randomised trial of cannulation technique in ERCP: effects on technical success & post ERCP pancreatitis.

(Lynch PM, Bailey AA, Lee EYT, Walsh PR, Murray MA, Kwan V, Williams SJ, Bourke MJ)

11.30-11.45

022

Risk factors for post-ERCP complication: results of a large scale prospective multi-centre study. (Williams EJ, Steering Committee, BSG Audit of ERCP)

11.45-12.00

023

Self reported experiences of 2059 patients undergoing ERCP; results of a multi-centre survey in 5 English regions. (Williams EJ, Steering Committee, BSG Audit of ERCP)

09.00-10.30

SERVICE DEVELOPMENT FREE PAPERS : Hall 9 : Chair –

Dr R Valori and

09.00-09.15

024

Is the two week cancer wait saving lives? a prospective follow-up of patients diagnosed with oesophago-gastric and pancreatic cancer In 2003. (Moran G, Iyer H, Bailey A, Butterworth JR (introduced by Bateman J)

09.15-09.30

025

Declining prevalence of cancer in two week wait referrals for suspected upper gastrointestinal malignancy. (Dewar DH, Sagili VBR, Wong TSN, Lynch T, Leong KM, Reffitt D, O'Donohue J)

09.30-09.45

026

Nurse-led versus GP led management of dyspepsia following direct access gastroscopy. (Chan D, Harris S, Roderick P, Brown D, Patel P)

09.45-10.00

027

Prospective audit of colonoscopy quality in Kent and Medway.

(Harris AW. Arais K, Rouse T)

10.00-10.15

028

Does screening decrease emergency admissions for colorectal cancer? a five year experience. (Menon A, Pedamallu S, Wong LS)

10.15.10.30

029

Audit of colonoscopy surveillance waiting list in a district general hospital: the benefit of BSG guidelines. (Johnson GJ, Edge V, Palmer J, Burke DA)

11.00-12.00

NEOPLASIA FREE PAPERS :  Hall 9 : Chair

11.00-11.15

030

Suppression of colonic epithelial apoptosis and crypt hyperplasia occurs in bak-null mice. (Duckworth CA, Pritchard DM)

11.15-11.30

031

Inhibition of VEGFR reduces polyp burden in the Apc^Min/+ mouse model of intestinal cancer. (Alferez D, Goodlad RA, Watkins AJ, Poulsom R, Ryan A, Wedge SR, Pyrah IT, Mandir N, Wilkinson RW)

11.30-11.45

032

Transgenic mouse model for P-cadherin expression. (Harrison LA,

Nye E, Stamp G, Wright NA, Goodlad R, Jankowski JA)

11.45-12.00

033

Gastrin and the CCK2 processing in neuroendocrine tumours and cell lines- therapeutic targets. (Khan K, Stubbs M, Shah T, Savage K, Dhillon AP, Caplin ME)

08.30-10.30

PAEDIATRIC SECTION SYMPOSIUM – ‘Advances in the Management of Intestinal Failure and Intestinal Transplantation’

Hall 10 : Chair – Professor D Kelly and Dr K Lindley

08.30-09.00

Protracted diarrhoea of infancy – What we have learnt about molecular genetics and physiology (Dr A Phillips, London)

09.00-09.15

034

Tumour necrosis factor α promoter polymorphisms influence disease phenotype and severity in childhood IBD. (Van Limbergen J,

Russell RK, Nimmo ER, Drummond HE, Anderson N, Wilson DC,

Gillett PM, McGrogan P, Hassan K, Weaver LT, Bisset WM, Mahdi G, Satsangi J)

09.15-09.30

035

ASCA positivity independently predicts oral Crohn’s disease in a large early onset IBD population. (Russell RK, Ip B, Aldhous MC, Drummond HE, Arnott IDR, McDougall M, Wilson DC, Gillett PM, McGrogan P, Hassan K, Weaver LT, Bissett WM, Mahdi G, Satsangi J)

09.30-10.10

Management of Intestinal failure – Challenges and opportunities

Paediatric experience (Dr N Meadows, London)

Adult experience        (Dr J Shaffer, Salford)

10.10-10.20

Discussion

10.20-10.40

Coffee

Chair : Dr S Murphy and Dr S Beath

10.40-10.55

036

Children requiring home  parenteral nutrition  (HPN) – how much time is really spent at home? (Ooi ET, Paxton C, Gillett PM, Munro FD,

Wilson DC ( introduced by Gillett H)

10.55-11.10

037

Diagnostic delay or failure in paediatric coeliac disease:a regional experience. (Gillett PM, Bradshaw CL, Russell RK, Satsangi J,

Wilson DC)

11.10-12.10

Is there a future for intestinal transplantation?

UK experience              (Dr G Gupta, Birmingham)

International experience (Dr A Langnas, Omaha)

12.10-12.20

Discussion

08.45-12.00

GASTRODUODENAL SECTION SYMPOSIUM – ‘Can we now predict and prevent gastric cancer?’ : Hall 11 : Chair – Professor KEL McColl and Dr M Walker)

08.45-09.10

Role of environmental factors (Professor D Forman, Leeds)

09.10-09.35

Genetic predictors – Are they useful ?  (Professor E El-Omar, Aberdeen)

09.35-10.00

Symptoms as predictors of curable cancer (Professor A Axon, Leeds)

10.00-10.30

Coffee

10.30-10.50

Can we now predict and prevent gastric cancer (Professor C Caldas,  Cambridge)

10.50-11.15

Gastric phenotype as predictor of gastric cancer (Dr M Walker, London)

11.15-11.45

Role of Helicobacter pylori in prevention of gastric cancer (Professor P Malfertheiner, Madgeburg)

11.45-12.00

Discussion

09.00-12.00

SMALL BOWEL AND NUTRITION FREE PAPERS : Hall 6 : Chair -

09.00-09.15

038

Plasma citrulline concentration: a simple, sensitive and non-invasive method to monitor small bowel absorptive function in patients with Crohn’s disease. (Papadia C, Sherwood RA, Kalanzakis T, Volta U, Fiorini E, Forbes A)

09.15-09.30

039

Coeliac disease (CD): is biopsy still required for diagnosis at all levels of IgA tissue transglutaminase antibody (TGA)? (Hill PG. Holmes GKT)

09.30-09.45

040

Intestinal dendritic cells (DC) in coeliac disease (CD). (Di Sabatino A, Pickard KM, Gordon JN, Beattie MR, Monteleone G, MacDonald TT)

09.45-10.00

041

Consideration of the blood supply of the ileo-caecal segment in valve preserving right hemicolectomy. (Fernando EDPS, Deen KI)

10.00-10.15

042

Push enteroscopy in the era of capsule endoscopy. (Sidhu R,

Horoldt BS, Hopper AD, McAlindon ME, Kapur K, Hurlstone DP, Wheeldon MC, Sanders DS)

10.15-10.45

Coffee

10.45-11.00

043

Nitrogen balance and urea kinetics in ileostomy patients. (Ng DHL, Wootton SA, Jackson AA, Stroud MA)

11.00-11.15

044

The significance of low urinary sodium excretion in ileostomy patients. (Ng DHL, Wootton SA, Jackson AA, Stroud MA)

11.15-11.30

045

The hypophagia and weight loss induced by Trichinella spiralis enteritis are TNFα independent. (Worthington J, Grencis RK, McLaughlin J)

11.30-11.45

046

The role of screening and antibiotic prophylaxis in the prevention of percutaneous gastrostomy site infection caused by methicillin resistant Staphylococcus aureus. (Thomas S, Cantrill S, Waghorn DJ,

McIntyre AS)

11.45-12.00

047

Why every Trust practicing parenteral nutrition should have a nutrition team. (Moran GW, Jones BJM)

10.30-12.30

INFORMATION TECHNOLOGY : Hall 7 : Chair – Professor J Brown

10.30-10.50

What are the ‘do once and share projects’ and how will they influence clinical practice? (Sir Muir Gray ??)

10.50-11.10

‘Do once and share’ and Endoscopy (Dr B Rembacken, Leeds)

11.10-11.30

‘Do once and share’ and inflammatory bowel disease (Dr I Shaw, Gloucester)

11.30-11.45

Discussion

11.45-12.10

National bowel cancer screening programme software demonstration (Professor J Brown, Gloucester)

12.10-12.30

IT methods and quality assurance in the independent sector (Professor J Brown,Gloucester)

14.00-14.30

Hall 1

STATE-OF-ART LECTURE –

‘Endoscopic management of adenomas of the duodenal papilla’

Professor N Soehendra, Hamburg

(introduced by Dr RH Teague)

14.30-16.30

JOINT BSG/ESGE SYMPOSIUM – ‘New technologies and treatments in endoscopy’ : Hall 1 : Chair – Dr AJ Morris and Dr R Teague

14.30-14.55

Optimising current endoscopic technique (Professor J-F Rey, France)

14.55-15.20

New endoscopic technology – what does it add?

 (Professor L Aabakken, Oslo)

15.20-15.45

New treatments – EMR/PDT in oesophageal disease

 (Professor T Rosch, Berlin)

15.45-16.10

New insights – capsule endoscopy and double balloon enteroscopy (Professor C Mulder, Amsterdam)

16.10-16.30

BSG/ESGE Panel discussion

14.30-17.30

INFLAMMATORY BOWEL DISEASE FREE PAPERS : Hall 5 : Chair – Dr J Satsangi, Dr S Bloom, Dr CJ Probert and Dr M Parks

14.30-14.45

048

Are all mesalazines equal? a meta-analysis of pH7-dependant versus controlled-release mesalazine in the maintenance of medically induced remission of inactive Crohn's disease. (Steinhart AH, Forbes A, Bhatt A, Travis SPL)

14.45-15.00

049

Transforming growth factor (TGF) –β signaling and matrix metalloproteinase (MMP) pattern in intestinal strictures in Crohn's disease. (Di Sabatino A, Buckley M, Pickard KM, Morera R, Cazzola P, Corazza GR, MacDonald TT, Pender SLF)

15.00-15.15

050

Acute psychological stress increases rectal mucosal and LPS-stimulated blood release of TNF-α in patients with inactive UC. (Mawdsley JE, Rampton DS)

15.15-15.30

051

Expression of human defensin-5 in inflammatory bowel disease tissue. (Elphick DA, Mahida YR)

15.30-15.45

052

Mucosal E coli isolates from IBD mediate IL-8 release from colon epithelial cells by shed outer membrane vesicles containing flagellin. (Subramanian S, Rhodes JM, Hart CA, Tam B, Yu LG, Martin HM, Campbell BJ)

15.45-16.15

Tea

16.15-16.30

053

Remission and clinical response to open-label adalimumab over 1-year in patients with Crohn's disease (CD). (Lukas M, Hanauer SB, Macintosh DG, Pollack PF, Kent J (introduced by Ghosh S)

16.30-16.45

054

Gene-wide haplotypic analysis demonstrates novel association between ATP-Binding cassette 3/multidrug resistance protien 3 (ABCC3/MRP3) gene and inflammatory bowel disease. (Ho GT, Soranzo N, Nimmo E,

Tenesa A, Goldstein DB, Satsangi J)

16.45-17.00

055

Association of a nonsense mutation in the TUCAN (CARD8) gene with inflammatory bowel disease. (Mirza MM, Fisher SA, Onnie C, Sanderson J, Forbes A, Mansfield J, Lewis CM, Mathew CG)

17.00-17.15

056

Evidence of monoclonal origins in dysplasia in ulcerative colitis. (Leedham SJ, Maia LC, Sieber O, Preston SL, McDonald SAC, Tomlinson IPM, Wright NA)

17.15-17.30

057

Orofacial granulomatosis: a tertiary referral centre experience.

(Nunes C, Escudier M, Shirlaw PJ, Challacombe SJ, Sanderson JD)

14.30-17.30

SMALL BOWEL/NUTRITION SYMPOSIUM : ‘Imaging and hot topics in the small bowel’ : Hall 8 : Chair – Dr BJM Jones and

14.30-14.50

Capsule Endoscopy – luxury or necessity (Dr M McAlindon, Sheffield)

14.50-15.10

New imaging techniques in the small bowel (Dr P Rodgers, Leicester)

15.10-15.20

Tea

15.20-15.50

Coeliac disease update (Professor P Ciclitira, London)

15.50-16.20

Bile acids and the small bowel – friend or foe? (Dr KD Bardhan, Rotherham)

16.20-16.40

Grown factors and the small bowel (Dr J Nightingale, Leicester)

16.40-17.00

Small intestinal bacterial overgrowth and bowel function (Professor M Pimental, Los Angeles)

14.30- 17.00

PANCREATIC SYMPOSIUM ‘Precursors of pancreatic malignancy’ AND FREE PAPERS : Hall 9 : Chair – Dr K Oppong, Mr R Charnley and Dr C Verbeke

14.30-14.45

058

Early admission to ITU/HDU of patients with acute pancreatitis in England, 2003-04. (David G, Al-Sarira A, Cummins K, Corless DJ, Deakin M, Slavin JP)

14.45-15.00

059

Socio-economic status correlates with outcome in pancreatic cancer. (Brown JJS, Ashton B, Charnley RM, Forman D, Jaques BC)

15.00-15.30

PANINs and pancreatic cancer (Professor R Schmid, Munich)

15.30-16.00

Genetic predisposition to pancreatic cancer (Dr W Greenhalf, Liverpool)

16.00-16.30

Hormonal effects (Professor S Watson, Nottingham)

16.30-17.00

Is screening for pancreatic cancer worthwhile? (Professor M Canto, Baltimore)

14.30-17.30

PRIMARY CARE SOCIETY FOR GASTROENTEROLOGY : Hall 10 : Chair – Dr Richard Stevens and Professor Pali Hungin

14.30-15.00

Is Helicobacter pylori yesterday’s news? (Dr B Walt, Birmingham)

15.00-15.30

The Hepatitis C epidemic in the UK and Europe

(Professor W Rosenberg, Southampton)

15.30-16.00

Pharmacological and non-pharmacological treatments for the irritable bowel syndrome. (Professor R Jones, London)

16.00-16.15

Tea

16.15-17.30

The PCSG debate: ‘Public plus private sector care is better than public sector care alone for NHS patients with GI problems’

Proposer: Dr R Smith, Chief executive, United Health Europe

Seconder: Dr P Evans, Director of Jubilee Surgery Endoscopy Services

Opposer: Dr P Fisher, President of NHS Consultants Association

Seconder: Professor E Elias, BSG President 2005-6

14.30-17.00

PATHOLOGY/OESOPHAGEAL SYMPOSIUM : ‘The management of Oesophageal Neoplasia’ : Hall 11 : Chair – Professor N Shepherd and Dr A Ireland

14.30-15.00

Can we prevent the progression of dysplasia?   The role of photodynamic therapy (Dr L Lovat, London)

15.00-15.30

Treatment of dysplasia and early cancer by endoscopic mucosal resection (Professor H Barr, Gloucester)

15.30-16.00

Tea

16.00-16.30

How do we classify and treat junctional tumours (Mr R Hardwick, Cambridge)

16.30-17.00

New issues concerning the pathological reporting of oesophageal cancer (Dr N Mapstone, Lancaster)

17.05-17.35

BASIL MORSON LECTURE : Hall 1 :

‘The pathology of Barrett’s oesophagus: from metaplasia to cancer’ – Professor Jean-Francois Flejou, Paris

(introduced by Professor N Shepherd)

14.30-16.30

USING ROUTINE DATA IN GASTROENTEROLOGY : MAKING IT WORK FOR YOU.  Hall 7 : Chair – Dr L Shurlock and Professor JG Williams

Major investment in the IT and information infrastruction of the NHS is bringing with it the potential for much greater use f clinical and administrative data for a wide variety of purposes.  This session will demonstrate the potential use of routinely collected data to support research, audit, service development, training and appraisal.  The availability of the data will be discussed, together with its strengths and weaknesses, and opportunities in the future.

14.30

Welcome and introduction

14.40

What data are available? (Dr A Mason, RCP, London)

15.00

Use of routine data for research (Professor M Goldacre, Oxford)

15.20

Use of routine data to monitor performance and undertake audit (Professor M Pearson, RCP, London)

15.40

Use of routine data for appraisal (Dr GP Croft, RCP London)

16.00

Caveats and opportunities (Professor JG Williams, RCP London)

16.20

Discussion

09.00-11.50

BSG/BASL SYMPOSIUM ‘Alcoholic Liver Disease’ : Hall 1 : Chair – Professor AK Burroughs and Professor J Neuberger

09.00-09.15

The role of the alcohol nurse specialist (Dr M Holmes, Nottingham)

09.15-09.35

The impact of alcohol on the medical profession (Dr M Morgan, London)

09.35-09.45

Discussion

09.45-10.05

The epidemiology of alcoholic liver disease (Professor IT Gilmore, Liverpool)

10.05-10.25

The management of alcoholic hepatitis (Dr E Forrest, Glasgow)

10.25-10.35

Discussion

10.35-10.55

Coffee

10.55-11.15

Psychological interventions in alcoholic liver disease (Dr E Gilvarry, Newcastle)

11.15-11.35

Selection of the alcoholic liver patient for transplantation (Dr A Gimson, Cambridge)

11.35-11.50

The current government alcohol strategy (Dr J Coussin, The Portman Group)

11.50-12.00

Discussion

12.10-12.40

STATE-OF-ART LECTURE :

‘Budd Chiari Syndrome’ – Professor D Valla, Clichy

(introduced by Professor E Elias)

08.30-12.00

IBD/PATHOLOGY SECTIONS JOINT SYMPOSIUM : ‘Causes and course of Crohn’s disease’ : Hall 5 : Chair -

08.30-10.30

Chair : Professor N Shepherd and Dr S Travis

08.30-09.00

Molecular clues to the cause of Crohn’s disease (Dr T Ahmad, Oxford)

09.00-09.30

Histopathology in the prediction of relapse in Crohn’s disease (Professor K Geboes, Leuven)

09.30-09.45

060

Detection of muramyl dipeptide sensing pathway defects in patients with Crohn’s disease. (van Heel DA, Hunt KA, Ghosh S, King K, Gabe S, Mathew CG, Forbes A, Playford RJ)

09.45-10.00

061

IgG plasma cells in inflammatory bowel disease express large quantities of stromelysin (MMP-3). (Gordon JN, Pickard KM, Goggin PM, MacDonald TT)

10.00-10.30

Clinical and biochemical predictors of relapse in Crohn’s disease (Professor I Bjarnason, London)

10.30-11.00

Coffee

11.00-12.00

Chair : Professor S Ghosh and Dr B Warren

11.00-11.30

Mechanisms of intestinal repair and relevance to IBD (Professor R Playford, London)

11.30-12.00

Mechanisms of cancer development in IBD (Professor J Rhodes, Liverpool)

09.00-12.00

ENDOSCOPY FREE PAPERS AND VIDEOS : Hall 8 : Chair – Dr JRB Green

09.00-09.15

062

Position change improves luminal distension during colonoscope withdrawal: a randomised, crossover, blinded trial. (East JE, Suzuki N, Arebi N, Swain D, Palmer N, Bassett P, Saunders BP)

09.15-09.30

063

Intra-stricture injection of steroid for Crohn's anastomotic strictures post endoscopic balloon dilatation: results of a randomised, double-blind, placebo controlled trial. (East JE, Patterson N, Brooker JC, Rutter MD, Thapar C, Swain D, Bassett P, Rampton DS, Saunders BP)

09.30-09.45

064

Intraepithelial neoplasia and colon cancer detection is significantly improved and characterized using high magnification chromoscopic colonoscopy: do BSG Guidelines now require modification?

(Hurlstone DP, Sanders DS, McAlindon ME, Lobo AJ, Thomson M, Brown S, Cross SS)

09.45-10.00

065

Autofluorescence imaging (AFI) and narrow band imaging (NBI) with magnification in colonoscopy: an early experience. (East JE, Suzuki N, Palmer N, Thapar C, Swain D, Saunders BP)

10.00-10.15

066

Colonic polyp to cancer - an animated story. (Webster GJM, Doshi R, Ward AR)

10.45-12.00

Videos

09.00-12.00

ENDOSCOPY ASSOCIATES GROUP – ‘General anaesthetic, sedation or non’ : Hall 9 : Chair – Ms P Hutson and Ms W Pugh

09.00-09.30

Entonox vs sedation (Ms G Thompson)

09.30-10.00

Safe administration of propofol in an Endoscopy unit (Ms C Morley)

10.00-10.30

Training non-medics to administer propofol and its issues (Dr TK Daneshmend)

10.30-11.00

Coffee

11.00-11.30

Conscious sedation and throat spray : potentially fatal complications (Ms H Livett)

11.30-12.00

Recovery issues and safe discharge after GA procedures (Ms S Field)

09.00-12.00

ENDOSCOPY ASSOCIATES GROUP – ‘Adjevant therapies and nutrition’ : Hall 10 : Chair – Ms H Griffiths and Ms C Neumann

09.00-09.30

Hypnosis : its use in IBS treatment (Dr G Smith)

09.30-10.00

The role of bio-feedback in GI medicine (Ms J Duncan)

10.00-10.30

Large bowel venting with PEG tube (Dr A Emmanuel)

10.30-11.00

Coffee

11.00-11.30

Is it good or bad for you; the alternative diet talk (Professor A Forbes)

11.30-12.00

Nutritional support in adults; are the guidelines ‘Nice’? (Ms L Colagiovanni)

09.00-12.00

CLINICAL SERVICES AND STANDARDS COMMITTEE SYMPOSIUM : ‘Life as a Gastroenterologist in the 21^st Century’ Hall 11 : Chair – Dr I Barrison and Dr M Denyer

09.00-09.10

Introduction (Dr I Barrison)

09.10-09.30

Organising the endoscopy service (Professor AI Morris, Liverpool)

09.30-09.50

Job planning for new consultants (Dr A King, Hemel Hempstead)

09.50-10.10

Appraisal and revalidation (Professor IT Gilmore, Liverpool)

10.10-10.30

Discussion

10.30-11.00

Coffee

11.00-11.20

Complaints and litigation (Dr H Shepherd, Winchester)

11.20-11.40

How not to get what you want from the system (Dr DE Loft, Coventry)

11.40-12.00

Discussion

09.00-12.00

OESOPHAGEAL FREE PAPERS : Hall 6 : Chair – Dr A Ireland and Mr T Dehn

09.00-09.15

067

Shortening of the abdominal component of the lower oesophageal sphincter (LOS) following a meal. (Manning JJ, Wirz A, McColl KEL)

09.15-09.30

068

The clinical impact of prolonged (48 and 96-hour) oesophageal pH monitoring by the Bravo™ system. (Thakur A, Fox M, Anggiansah R, Anggiansah A, Wong T)

09.30-09.45

069

Oesophagitis is associated with enlarged unbuffered postprandial acid pocket. (Clarke AT, Wirz AA, Manning J, Ballantyne S, Alcorn D,

McColl KEL)

09.45-10.00

070

Are oesophageal peristaltic or lower oesophageal sphincter functions genetically determined in GORD? - a discordant co-twin case control study. (Mohammed I, Anggiansah A, Anggiansah R, Cherkas LF, Spector TD, Trudgill NJ)

10.00-10.15

071

Time trends in the prevalence & incidence of dysplasia in Barrett’s oesophagus (BO) over two decades. (Sonwalkar SA, Rotimi O,

Everett SM)

10.15-10.45

Coffee

10.45-11.00

072

Natural history of dysplasia in Barrett's oesophagus (BE). (Faisal W, Anagnostopoulos G, Kaye P, Logan R, Ragunath K)

11.00-11.15

073

Cancer risk in Barrett's oesophagus: a meta-analysis. (Thomas T, Abrams KA, de Caestecker J, Robinson RJ)

11.15-11.30

074

Argon plasma coagulation (APC) for Barrett's oesophagus (BO): long-term follow up. (Thomas T, Talwar V, Basu KK, de Caestecker J)

11.30-11.45

075

Reactive oxygen species-Induced DNA damage in osophageal adenocarcinoma. (Clemons NJ, Fitzgerald RC)

11.45-12.00

076

Photodynamic therapy of early oesophageal carcinoma. (Craig C, Macpherson M, Hodgson H, Gray J, Zammit M, Fullarton GM)

09.00-10.15

NEUROGASTROENTEROLOGY AND MOTILITY FREE PAPERS  : Hall 7 : Chair – Dr J McLaughlin and Dr Q Aziz

09.00-09.15

077

A dose response trial of pharyngeal stimulation for the treatment of dysphagia post stroke. (Singh S, Power M, Tyrrell P, Thompson DG, Hamdy S)

09.15-09.30

078

Hypersensitivity against intragastric Capsaicin in patients with non-ulcer dyspepsia. (Hammer J, Matiasek J, Ban S)

09.30-09.45

079

Differential selective autonomic responses in visceral and somatic pain. (Paine PA, Worthen SF, Hobson AR, Thompson DG, Gregory LJ, Phillips ML, Williams S, Aziz Q)

09.45-10.00

080

Gut response to stress can be pharmacologically modulated - amitriptyline modifies visceral hypersensitivity in irritable bowel syndrome. (Murray CDR, Tripoli E, Pitcher MCL, Kamm MA, Emmanuel AV)

10.00-10.15

081

Pregabalin, a second generation α2δ ligand reduces hypersensitivity to rectal distension in patients with irritable bowel syndrome. (Houghton LA, Fell C, Lea R, Whorwell PJ, Jones I, Sudworth DP, Gale JD)

10.45-12.00

COLORECTAL FREE PAPERS : Hall 7 : Chair -

10.45-11.00

082

Can artificial neural networks predict which patients need a colonoscopy. (Maslekar S, Gardiner A, Duthie GS)

11.00-11.15

083

Assessment of inflammation within sporadic colorectal polyps.

(McLean MH, Murray GI, Fyfe N, Hold GL, Mowat NAG, El-Omar EM)

11.15-11.30

084

Expression of cyclooxygenase-2(COX-2) in human sporadic colorectal adenomas. (McLean MH, Murray GI, Fyfe N, Hold GL, Mowat NAG,

El-Omar EM)

11.30-11.45

085

Mitochondrial DNA (mtDNA) mutations in human colonic crypts: a novel biomarker of colorectal cancer (CRC). (Arasaradnam RP, Greaves LC, Commane D, Mathers JC, Taylor RW, Turnbull DM)

11.45-12.00

086

Evaluation of autofluorescence colonoscopy for the detection and diagnosis of colonic polyps. (McCallum AL, Jenkins JT, Gillen D,

Molloy RG)

14.00-17.30

PLENARY SESSION : Hall 1 : Chair – Professor E Elias and Dr J de Caestecker

14.00-14.30

SIR ARTHUR HURST MEMORIAL LECTURE:

‘Ulcerative colitis before and after Hurst – the cycle of history’ (Professor DP Jewell, Oxford)

14.30-14.45

087

Alpha-fetoprotein specific CD4⁺ T cell responses are unmasked during transarterial embolisation in hepatocellular carcinoma. (Ayaru L,

Pereira SP, Meyer T, Davidson BR,  Burroughs AK, Williams R, Behboudi S)

14.45-15.00

088

Real-time imaging and functional analysis of human colonic crypt renewal ex vivo. (Parris A, Reynolds A, Spahos A, Munsterberg A,

Tighe R, Lewis M, Cook J, Prior A, Speakman C, Stebbings HJ,

Ellamin K, Williams M)

15.00-15.30

SIR FRANCIS AVERY JONES BSG RESEARCH MEDAL

‘Enteroendocrine cells : at the frontier of gut-brain signalling’ (Dr J McLaughlin, Manchester)

15.30-15.35

President’s Medal Award

15.35-15.40

CORE Award

15.40-15.45

Induction of Professor AI Morris, President 2006-7

15.45-16.15

Tea

16.15-16.30

Update on BSG framework document (Dr MD Hellier)

16.30-16.45

089

Improving the experience of patients having an endoscopy with the endoscopy global rating scale. (Valori RM, Johnston D, Tailor V)

16.45-17.00

090

Aspirin for the prevention of recurrent colorectal adenomas – results of the ukCAP trial. (Logan RFA, Muir KR, Grainge MJ, Shepherd V)

17.00-17.30

NEW PERSPECTIVES LECTURE:

‘Why the liver scars’   (Professor D Brenner, New York)

17.40

Annual Business Meeting : Hall 1

14.00-16.30

GASTROINTESTINAL  PHYSIOLOGY ASSOCIATES GROUP : Hall 8 : Chair – Dr RC Heading and Ms J Barlow

14.00-14.15

091

Ingested lipid modulates hypothalamic and brainstem neuronal activity in man. (Lassman DJ, McKie S, Gregory LJ, Dockray GJ, Williams S, Thompson DG)

14.15-15.00

Keynote Lecture :

Advances in the diagnosis of GORD in children : Impedance, pepsin and the rest’ (Dr M Thomson, Sheffield)

15.00-15.30

Tea

15.30-16.15

Keynote Lecture :

GORD: Does it really cause laryngeal symptoms? (Professor J Wilson, Newcastle)

16.15-16.30

092

Acetylcholine stimulation of the NKCC1 transporter is calcium-dependent and is rapidly desensitised by endocytosis: implications for intestinal fluid secretion. (Reynolds A, Parris A, Tighe R, Lewis M, Westgarth D, Bell D, Jamieson C, Murray K, Southgate J, Sargen K, Williams M)

14.00-17.00

ENDOSCOPY ASSOCIATES GROUP – Free papers, national awards, sharing good clinical practice’ : Hall 9 : Chair – Mr J Brown, Ms M Baulf and Ms A Reilly

14.00-15.00

Free papers

15.00-15.30

Tea

15.30-16.30

Free papers

16.30-16.45

CORE Research Grant Winner : Cost of variceal bleeding to the NHS (Ms L Cheshire)

16.45-17.00

Irene Cooper Prize

14.00-16.30

ENDOSCOPY ASSOCIATES GROUP – ‘New management challenges’ : Hall 11 : Chair – Ms L Melleney and Mr W Chapman

14.00-14.30

Usefulness and efficacy of Endoscopy storage/drying cabinet (Dr L Pineau, Marseilles)

14.30-15.00

KSF; competencies framework (example in practice) (Mr D Hart)

15.00-15.30

Tea

15.30-16.00

Endoscopy competence framework; skills for health (Ms D Campbell)

16.00-16.30

Discussion

14.00-17.00

PATHOLOGY EQA AND SLIDE SEMINAR : Hall 6

08.30-11.30

ETHICAL ISSUES IN ENDOSCOPY : Hall 1 : Chair – Dr RH Teague

08.30-10.00

Part 1 : Chair – Dr MC Allison

Panel : Dr D Sanders, Dr P O’Toole, Ms Di Campbell, Mr B Leigh

08.30-09.00

Case scenario 1 : Is there a role for PEG in dementia? (Dr D Sanders, Sheffield)

09.00-09.30

Case scenario 2 : Futile PEGs; lessons from NCEPOD (Dr P O’Toole, Aintree)

09.30-10.00

Just because you can do it doesn’t always mean you should (Dr KR Palmer, Edinburgh)

10.00-10.30

Coffee

10.30-11.30

Part 2 : Chair – Dr ET Swarbrick

Panel : Professor H Shepherd, Dr KR Palmer, Dr M Deakin, Ms Di Campbell, Mr B Leigh

11.30-11.00

Case scenario 3 : ERCP: between a rock and a hard place (Dr H Shepherd, Winchester)

11.00-11.30

How to avoid trouble (Mr B Leigh, Hempsons’s Solicitors, London)

11.30-12.00

HOPKINS ENDOSCOPY PRIZE :

‘Improving surveillance for colorectal cancer in ulcerative colitis : The colonoscopist is the key’ (Dr M Rutter, Stockton-on-Tees)

12.10

STATE OF ART LECTURE

‘Pharmacogenomics in inflammatory bowel syndrome’

Professor M Camilleri, Minnesota

(introduced by Professor RC Spiller)

09.00-12.00

NEUROGASTROENTEROLOGY/ MOTILITY SECTION SYMPOSIUM : ‘Treatment of irritable bowel syndrome : Past, present and future’  : Hall 5 : Chair – Dr LS Houghton and Dr A Emmanuel

Do current approaches work?  Role of antispasmodics, laxatives, fibre and antidepressants (Professor P Whorwell, Manchester)

09.25-09.50

Serotonin and its modulation in the management of irritable bowel syndrome (Dr L Houghton, Manchester)

09.50-10.15

Psychological approaches to the management of irritable bowel syndrome (Professor F Creed, Manchester)

10.15-10.45

Coffee

10.45-11.10

Stress and the HPA axis: potential targets (Dr H Monnikes, Berlin)

11.10-11.35

Probiotics in irritable bowel syndrome (Professor E Quigley, Cork)

11.35-12.00

Novel targets for irritable bowel syndrome : drugs on the horizon (Dr P Holzer, Austria)

09.00-10.35

COMBINED BSG AND BRITISH ASSOCIATION FOR ANTIMICROBIAL CHEMOTHERAPY : ‘Helicobacter pylori testing and treating – Practical issues’ :Hall 8 : Chair – Dr M Walker and Professor KEL McColl

09.00-09.15

Which test for ‘test and treat’ in dyspepsia ?  Serology vs breath test vs stool antigen test (Dr L Teare, Chelmsford)

09.15-09.30

Is ‘test and treat’ really better than endoscopy ? (Professor B Delaney, Birmingham)

09.30-09.45

Is ‘test and treat’ working in primary care ?  (Professor P Hungin, Stockton-on-Tees)

09.45-10.25

How do you manage the patient with stubborn Helicobacter pylori infection ?

Case presentations (Professor KEL McColl, Glasgow)

Role of sensitivity testing (Dr R Owen, London)

Which 2^nd, 3^rd line and rescue therapies should we use ? (Dr C McNulty, Gloucester)

10.25-10.35

Discussion

10.45-11.15

Coffee

11.15-12.30

GASTRODUODENAL FREE PAPERS : Chair – Dr EM El-Omar and Dr D Gillen

11.15-11.30

093

Predicting clinical outcome in upper gastrointestinal bleeding complicating low-dose aspirin and anti-thrombotic therapy. (Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O)

11.30-11.45

094

Helicobacter pylori infection confers an increase in ten-year mortality from all causes: data from a community screening programme.

(Ford AC, Bailey AG, Forman D, Axon ATR, Moayyedi P)

11.45-12.00

095

Innate immune response gene polymorphisms and their role in H pylori-induced precancerous changes. (Smith MG, Hold GL, Berry SH,

 McColl KE, El-Omar EM)

12.00-12.15

096

Gastrin increases mcl-1 expression in AGS-_GR gastric epithelial cells to cause suppression of apoptosis. (Przemeck S, Varro A, Pritchard DM)

12.15-12.30

097

The magnitude of viscero-visceral and viscerosomatic sensitisation induced by intra-duodenal capsaicin infusion is dose dependent. (Unsworth BJ, Aziz Q, Holzer P, Hobson AR)

10.30-12.00

FUTURE OF ACADEMIC GASTROENTEROLOGY : RESEARCH AND ACADEMIC PROGRAMMES FOR GASTROENTEROLOGISTS :  DEBATE led by Professor David Brenner, Professor DG Thompson and Professor E Elias – Hall 7

08.30-12.00

INFLAMMATORY BOWEL DISEASE SECTION SYMPOSIUM : ‘What’s new in IBD 2006?’  : Hall 9

Chair : Dr J Lowes and Dr R Cowan

08.30-09.00

Classification of inflammatory bowel diseases – a new perspective (Professor J Satsangi, Edinburgh)

09.00-09.30

From mice to men : biotherapy update(Dr D Rampton, London)

09.30-09.45

098

Fully-human anti-TNF adalimumab maintains remission for 1 year in patients with active Crohn's disease (CD): a randomised, controlled cohort. (Rutgeerts P, Sandborn WJ, Lukas M, Pollack PF, Kent J (introduced by Ghosh S))

09.45-10.00

099

Mesalazine (5-ASA), but not hydrocortisone, inhibits E coli-induced IL-8 release from colonic epithelial cells at therapeutic concentrations. (Subramanian S, Campbell BJ, Martin HM, Hart CA, Yu LG,

Rhodes JM)

10.00-10.30

Why are some patients refractory to steroids? (Professor D Franchimont, Montreal)

10.30-11.00

Coffee

11.00-11.30

Has mesalazine had its day? (Professor A Forbes, London)

11.30-12.00

Interface between biotherapy and immunomodulators (Professor Marc Lemann, Paris) [Professor Lemann’s travel expenses have been generously paid by Schering Plough Pharmaceuticals]

09.00-12.00

ENDOSCOPY ASSOCIATES GROUP – ‘New clinical practices in your region’ : Hall 10 : Chair – MsI Dunkley and Ms F Payton

09.00-12.00

Views from the regional groups

09.00-09.20

Region : East Anglia

‘Lessons learned from organising and hosting study days’ (Ms D Beesley)

09.20-09.40

Region : Scotland

‘A new start for Scotland : feedback from Endoscopy’ (Ms K Linton)

09.40-10.05

Region : North East

‘New kids on the block?’ (Ms L Hodgson)

10.05-10.20

Region : Humberside

‘What happened?’ (Ms L Godfrey

10.20-10.40

Coffee

10.40-11.00

Region : Northern Ireland

‘Audit of decontamination and traceability procedures in Endoscopy – N Ireland hospitals’ (Ms M O’Neill)

11.00-11.20

Region : Midlands

11.20-11.40

Small Channel Group

11.40-12.00

Discussion

09.30-12.30

ENDOSCOPY ASSOCIATES GROUP – ‘Service improvement’ : Hall 11 : Chair – Ms S Harnden and Dr R Valori

09.30-10.00

21^st century unit design; what does it take (Ms L Thomson)

10.00-10.30

Endoscopy in the independent sector (Ms J Yeates)

10.30-11.00

Tea

11.00-11.30

GRS; achieve top marks (Dr R Valori)

11.30-12.00

European guidelines on microbiological testing in Endoscopy (Ms C Neumann)

12.00-12.30

EAG Annual Business Meeting

09.00-12.00

CELL/MOLECULAR BIOLOGY FREE PAPERS : Hall 6 : Chair -

09.00-09.15

100

Deoxycholic acid damages DNA through it’s production of reactive oxygen species (ROS): antioxidants prevent this damage. (Jenkins G, D'Souza F, Alhamdani A, Griffiths P, Baxter J)

09.15-09.30

101

Monoclonal conversion of human gastric glands gives insights into stem cell and clonal architecture. (McDonald SAC, Greaves LG, Leedham SJ, Yin-Lee C, Deheragoda M, Oukrif D, Novelli MR, Taylor RW,

Turnbull DM, Jankowski JAZ, Wright NA)

09.30-09.45

102

Use of growth hormone releasing peptide-6 for the prevention of hepatic and multi organ failure. (Cibrian D, Ajamieh H, Berlanga J, Leon OS, Alba JS, Kim MJT, Marchbank T, Boyle JJ, Freyre F,

Garcia del Barco D, Lopez-Saura P, Guillen G, Ghosh S, Goodlad RA, Playford RJ)

09.45-10.00

103

Hyperammonemia alters the LPS-induced activation of TNF-α in peripheral blood mononuclear cells (PBMCs)

(Mathew RG, Shawcross DL, Davies NA, Hodges SJ, Jalan R)

10.00-10.15

104

Colonic stem cells are unable to selectively segregate genome at the time of mitosis: replication errors survive. (Preston SL, Mandir N,

Hunt T, Goodlad RA, Leedham SJ, Wright NA, Alison MR)

10.15-10.30

105

Targeted killing of colorectal cell lines and murine adenomas using a monoclonal antibody against membrane-bound carcinoma embryonic antigen (CEA). (Conaghan PJ, Wilding JL, Tytherleigh MG, Tchilian E, Mortensen NJMcC, Bodmer WF)

11.00-12.00

PATHOLOGY FREE PAPERS : Hall 6 : Chair

11.00-11.15

106

Evolution of Helicobacter pylori virulence factors in individuals and families from an isolated African population. (Hale JL, Argent RH, Robinson K, van der Merwe S, Atherton JC)

11.15-11.30

107

Human regulatory T-cell responses are associated with protection from Helicobacter pylori-induced peptic ulcer disease. (Kenefeck R,

Robinson K, Atherton JC)

11.30-11.45

108

The stomach peri-glandular fibroblast sheath expands in inflamed tissue before development of intestinal metaplasia. (Leedham SJ,

Deheragoda MG, Brittan M, Direkze NC, Preston SL, McDonald SAC, Wright NA)

11.45-12.00

109

Routine elastic staining assists detection of vascular invasion in colorectal cancer. (Kaye PV, Abdulkader M, Abdulla K, Rakha E)

13.30-16.00

BOWEL CANCER SCREENING AND QUALITY ASSURANCE IN ENDOSCOPY – Hall 1 : Chair – Dr R Valori and Dr R Teague

13.30-13.50

The bowel cancer screening programme (Mrs J Patnick, Director; NHS Cancer Screening Programmes)

13.50-14.20

Assessing the quality of the service :

Assessing the quality of the patient experience (Dr R Valori, Gloucester)

JAG accreditation of endoscopy units (Dr K Palmer, Edinburgh)

Panel discussion

14.20-15.10

Assessing the quality of individuals :

Using competency frameworks for assessment (Ms D Campbell, Torbay)

Certification of endoscopists (Mr R Leicester, London)

Revalidtion of established colonoscopists (Dr B Saunders, London)

Assessing the quality of the trainer (Professor JR Barton, North Shields)

Panel questions

15.10-15.50

Monitoring and improving performance :

Using the GRS knowledge management system to improve performance (Ms D Johnston, Gloucester)

Monitoring quality and safety indicators to improve performance (Dr B Rembachen, Leeds)

Improving quality through peer review (Dr R Teague, Torbay)

Panel discussion

15.50-16.000

Concluding remarks (Mrs J Patnick)

Close

14.00-16.30

ENDOSCOPY ASSOCIATES GROUP – ‘Nurse lead therapeutic services’ : Hall 9 : Chair – Dr B Saunders, Dr ET Swarbrick and

Ms S Harnden

14.00-14.30

Training issues in therapeutic colonoscopy (Ms K Smith)

14.30-15.00

On call GI bleed service (Ms S Harnden)

15.00-15.30

Tea

15.30-16.00

Oesophageal dilatation and EUS Service (Ms L Doig)

16.00-16.30

Endoscopy Nurse Practitioner’s role in therapeutic Endoscopy services (Dr B Saunders and Dr ET Swarbrick)

14.00-16.30

ENDOSCOPY ASSOCIATES GROUP – ‘Developments in GI disease’ : Hall 10 : Chair – Dr I Penman and  Ms A Reilly

14.00-14.30

Hepatitis C and liver transplantation (Ms M Nelson)

14.30-15.00

To quit or not to quit?  A stop smoking service for GI patients (Ms S James)

15.00-15.30

Tea

15.30-16.30

New variant CJD; implications for Endoscopy units (Professor MG Bramble, Dr M Allison, Ms T Bradley)

110

Beware of the diagnostic imitation in dysphagia. (Radhakrishnan NV,

Ellul P, Winarso P, Barlow J, Akhtar K, Sebastian BJ, George R)

111

An unusual endoscopic duodenal appearance. (Willert RP,

Weerasinghe SM, Lynch DAF)

112

An unusual cause of facial swelling in a jaundiced patient. (Gasem J,

Khalid S, Babores M)

113

A rash can cause GI bleeding? (Parr J, Burke DA, Macdonald CE)

114

A fatal pulmonary embolism secondary to a rare small bowel infection. (Shenoy AH, Shepherd NA, Brown JL)

115

A bleeding catch-22. (Pritchard G, Roche E, Foster P)

116

An unusual cause of upper GI bleed. (Mannath J, Shaw IS)

117

Raised serum hCG - an acute surgical problem. (Sebastian BJ,

Barnes NLP, Mittappali D, Hussain M, Aly S, Radhakrishnan NV, Winarso P, George R, SenapatiI PSP)

118

A fluke diagnosis? (Lawson AJ, Zaitoun A, Aithal GP)

119

An unusual cause of constipation. (Basavaraju KP, Musa MS,

Pickersgill A, Morgan KG, Ahluwalia NK)

120

An interesting case of jaundice with multisystem involvement. (Peddi KK, O'Riordan D)

121

A belly full of beaujolais - an unusual case of ascites. (Farmer AD, Redford D, Butterworth JR)

122

Skin blisters and liver. (Reddy Y, Das D)

123

Capsule endoscopy: friend or foe? (Wood E, McCartney S, Bloom S)

124

An unusual presentation of chronic diarrhea. (Dias A, Eryian G, Cropley I, Epstein O)

PLENARY

Poster round will be conducted by Professor E Elias, Professor AI Morris, Dr J de Caestecker and Dr A Harris

125

Role of  protein kinase C in aldosterone-induced non-genomic inhibition of basolateral potassium channels in  human colonic crypts. (Linley JE, Bowley KA, Robins GG, Hunter M, Sandle GI)

126

EGFR inhibition improves Helicobacter pylori induced pathology and epithelial cellular kinetics in vivo. (Crabtree JE, Jeremy AHT, Danjo K, Dixon MF, Robinson PA)

127

The colorectal nurse practitioner training in colonoscopy and polypectomy. (Castle MT, Ragunath K, Balfour T, Scholefield JH)

128

The threat to specialist training from the European working time directive: results from the BSG training committee survey of SpRs. (Hayee BH, Forgacs IC)

129

The effect of food composition and preparation on reflux severity in patients with reflux disease. (Fox M, Barr C, Nolan S, Anggiansah A, Lomer M, Wong T)

130

The Mallory Weiss Tear. (Thomson JM, Armour DL, Masson J,

Fraser A, Mowat NAG)

131

Attentional modulation of visceral and somatic pain. (Dunckley P,

Aziz Q, Wise RG, Brooks J, Tracey I, Chang L)

132

Developing a novel stimulation paradigm for enhancing human brain-swallowing pathways. (Singh S, Mistry S, Rothwell J, Thompson DG, Hamdy S)

133

Who consults with dyspepsia? a ten-year cross-sectional survey.

(Ford AC, Bailey AG, Forman D, Axon ATR, Moayyedi P)

134

Decompensated alcoholic liver disease (ALD) determinants of subsequent drinking behaviour. (McFarlane E, Gellion C, Jones J, Skinner J, Gleeson D)

135

A study to assess expertise and training in transcutaneous liver biopsy amongst trainee gastroenterologists. (Marden PF, Colleypriest B, (introduced by Robertson D)

136

Prevalence and characteristics of overlap syndromes in autoimmune liver disease, a twenty-year cohort from a defined community in South Wales. (Czajkowski MA, Kingham JGC)

137

Remifentanil versus midazolam and pethidine sedation during colonoscopy: a prospective, randomized study. (Manolaraki M,

Paspatis GA, Vardas E, Theodoropoulou A, Oustamanolakis P,

Gritzali A, Anastasiadou A)

138

Is a photograph of the caecum or terminal ileum reliable enough for documenting completion of colonoscopy? - a prospective study. (Guruswamy R, Skinner J, Brett B)

139

No evidence of IBD association at MDR1 or NOD1 in East Anglian IBD panel. (Tremelling M, Hancock L, Bredin F, Waller S, Parkes M)

140

Comparison of time to symptom resolution with oral mesalazine

4.8 g/day (800 mg tablet) versus 2.4 g/day (400 mg tablet): analysis of data from two randomised, double-blind, clinical trials in patients with moderately active ulcerative colitis. (Marion JF, Safdi M., Schwartz DA, Regalli G, Eusebio R, Law L (introduced by Ghosh S)

141

Cancer risk of low-grade dysplasia in chronic ulcerative colitis:

a meta-analysis. (Thomas T, Abrams KA, Robinson RJ, Mayberry JF)

142

Probiotic bacteria inhibit epithelial cell IL-8 production:role of TLR receptor engagement. (Hudspith BN, Rouzaud G, Gibson GR,

Rayment NB, Petrovska L, Bruce K, Sanderson JD, Brostoff J)

143

Evidence for different regulation of ileal bile acid transporter transcripts in patients with chronic diarrhoea. (Balesaria S, Chavele KM, Khair U, Walters JRF)

LIVER

Poster Round will be conducted by ???????????????????????

144

H63D mutation and liver disease. (Reddy Y, Hunt R, Das D)

145

Regeneration is increased in JNK2 knockout liver. (Bates CM, Henderson NC, Simpson KJ (introduced by Hayes PC)

146

Practical modifications of the ¹³C-methacetin breath test still fullfill clinical demands for the quantitative assessment of liver function. (Braden B, Schneider A, Dietrich CF, Caspary WF, Kueker W,

Sarrazin C)

147

Covered stent grafts for TIPS insertion provide improved clinical outcome: a decade of experience. (Masson S, Mardini H, Rose J, Record CO)

148

Acute lver failure in Scotland- thirteen year observational study.

(Bates CM, Davidson JS, Simpson KJ (introduced by Hayes PC)

149

What is the delay to diagnosis in patients referred with abnormal liver biochemistry? (Maida M, Unigwe S, Rajak R, Hocking R, Yassin L, Crimmins R, Green JT, Swift G)

150

Non-invasive markers of  fibrosis in NAFLD: a systematic review. (Guha IN, Parkes J, Roderick PJ, Rosenberg WM)

151

Serum undercarboxylated prothrombin (PIVKA II ) has an inverse relationship with hepatic steatosis. (Baburajan B, Li A, Mahadeva U, Tong W, Rangarajan S, Shearer M, Savidge G, Wong T)

152

Elevated alanine transaminase level in newly diagnosed Type 2 diabetes is associated with obesity and high triglyceride level and not glycaemic control. (Williams EJ, Thomas PW, Masding MG,

(introduced by Snook JA))

153

Is the metabolic syndrome a useful criterion in the decision to biopsy in non alcoholic fatty liver disease? (Barker S, Farrant M)

154

Lamivudine in acute Hepatitis B infection: a case series. (Hussain R, Fisher NC)

155

Resistance and sensitivity to insulin affect the response to interferon in patients with chronic Hepatitis C (CHC). (Samonakis DN, Koulentaki M, Xidakis C, Manousou P, Moschandreas J, Voumvouraki A, Tzardi M, Antoniou P, Kouroumalis EA)

156

Activation of effector CD8+ T cells from the liver tissue microenvironment in patients with chronic viral hepatitis. (Kennedy PTF, Gehring A, Patch D, Selden C, Rees M, Dusheiko G, Bertoletti A)

157

Nurse consultant led Hepatitis C management in a large DGH.

(Nayar MK, Madigan P, Mclindon J, Chandy R)

158

Serial measurements of hyaluronic acid - a useful marker of cirrhosis in Hepatitis C patients. (McAvoy NC, Dennis R, Hayes PC)

159

Hepatitis C care: are we achieving what we think? a report from a single centre viral hepatitis clinic 1995-2004. (Neilson M, Joyce T, Stanley AJ, Forrest E, Mackie J, Morris AJ)

160

European liver fibrosis markers accurately distinguish fibrosis severity in chronic Hepatitis C. (Parkes J, Cross R, Harris S, Ryder S, Irving W, Zaitoun A, The Trent Hepatitis C Research Group, Rosenberg WMC)

161

An epidemiological study of Hepatitis C genotype related to urban/rural living. (Dibb MJ, Oakey RJ, Higham AD, Brown CM, Keating JJ)

162

Late spontaneous clearance of Hepatitis C. (Thurairajah PH, Hegazy D, Kaminski E, Demaine A, Cunningham R, Cramp ME)

163

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with Hepatitis C. (Höroldt B, Haydon G, O’Donnell K, Dudley T, Nightingale P, Mutimer D)

164

Why is gammaglutamyltranspeptidase activity increased in patients with chronic Hepatitis C? (Lanzini A, Benini F, Bercich L, Pigozzi MG, Romanini L, Donati P, Pozzi A, Lanzarotto F, Ricci C)

165

Management of variceal bleeding: a single centre experience

(Holmes J, Tripath D, Hayes PC)

166

Sporadic Hepatitis E is more common that previously thought: a single centre experience. (Thurairajah PH, Samreen I, Stableforth W, Cunningham R, Teo CG, Dalton H, Mitchell J)

167

A systematic review of acute Hepatitis E virus infection in a semi-rural population in the UK. (Fogden EN, Shah A, Gröning J, Hall MJ, Edmondson S, Ransford RAJ)

168

Hepatotoxicity associated with atorvastatin use. (Clarke AT, Mills PR)

169

High prevalence of histological abnormalities is common in incidentally removed gallbladders. (Riyad K, Subar D, Mitchell T, Hussaini A, Vadeyar H, Sherlock D)

170

Association between coeliac disease and primary biliary cirrhosis.

(Baird K, Das D, Reddy Y)

171

Hospital admission rates in England for autoimmune hepatitis and primary biliary cirrhosis 1989/90 to 2002/03. (Al-Naeeb Y, Westlake S, Majeed A, Forton D, Maxwell JD, Kang JY)

172

Does Celts reached Rome on the east side of Appennini mountains? an open population screening study for HFE gene major mutations in central Italy. (Rosa Rizzotto E, Floreani A, Basso D, Navaglia F,

Petridis I, Di Andrea O, Testa R, Marra C, Chiaramonte M)

173

Does venesection and subsequent iron depletion reverse arterial stiffening seen in hereditary haemochromatosis? (Cash WJ,

McDougall N, McCance D, Young IS, Callender ME)

174

A prospective audit into the incidence, diagnosis and treatment of spontaneous bacterial peritonitis in cirrhotic inpatients with ascites in a UK hospital. (Pettitt E, Raza M, Brown M, Harding J, Challenor C, Heyderman RH, Jones RL)

175

Morbidity and mortality associated with alcoholic liver disease (ALD) following admission to St George’s Hospital HDU/ICU. (Cowan M, Tilliard A, Cook M, Clark S, Forton D, Grounds M, Rahman TM)

176

Decompensated alcoholic liver disease (ALD): factors associated with medium-term mortality following hospital discharge. (McFarlane E, Gellion C, Jones J, Skinner J, Gleeson D)

177

Decompensated alcoholic liver disease (ALD): accuracy of Glasgow, MELD, Maddrey and Child prognostic scores. (Kerss J, McFarlane E, Jones J, Gleeson D)

178

Mortality and morbidity trends due to alcoholic liver disease in a district general hospital population in North Eastern UK. (Maitra S,

Chaudhury BK, Kurmani M, Bhattacharjee KD, Berthou C, Singh SK, Sathyanaryana V, Vasani J)

179

Does the Glasgow alcoholic hepatitis score (GAHS) accurately predict survival in severe alcoholic hepatitis? (Austin AS, Kaye P, Aithal GP, Ryder SD)

180

Heterogeneity of liver histology in severe alcoholic hepatitis diagnosed on clinical criteria. (Austin AS, Kaye P, Aithal GP, Ryder SD)

181

‘Alcoholic Hepatitis' after gastro-intestinal bleeding has a good prognosis. (Lafferty H, Johnson V, Keith R, Morris AJ, Stanley AJ, Forrest EH)

182

Contrast-enhanced ultrasound in the management of focal liver lesions. (Pujar K, Marudanayagam R, Cochlin D, Kumar N)

183

Is insertion of uncovered transjugular intrahepatic porto systemic stem shunts (TIPSS) really a risk factor for development of hepatocellular carcinoma (HCC)? (Kochar N, Tripathi D, Delahooke TE, Redhead DN, Ireland H, Hayes PC)

184

Neoadjuvant therapy with oxaliplatin based regimens for downstaging of colorectal liver metastasis does not reduce viability of hepatocytes. (Riyad K, Pattenden C, Subar D, Trafford J, Brailsford C, Kingston S, Crees G, Patel R, Peak S, Saunders M, Vadeyar H, Sherlock D)

185

Prevalence and management of anaemia after liver transplantation. (Preston C, Mills V, Arundel M, McVerry A, Millson C)

186

Post operative course after liver resection is not influenced by the use of portal inflow compression (Pringle’s Manoeuvre). (Patil V, Ali M,

Riyad K, Subar D, Vadeyar H, Sherlock D)

187

Anthropometric markers and outcome from liver transplant. (Oliver DG, Barbour J, Davidson B, Manas D, Thompson NP)

188

Prognosis in adult patients with chronic liver disease  requiring ICU admission and those admitted for transplant assessment. (Austin M, Bernal W, Auzinger G, Sizer E, Wendon J)

PANCREAS

Poster Round will be conducted by Mr T Brown and Dr G Webster

189

Evaluation on a Mexican cohort of a UK computer model developed to predict severity of acute pancreatitis. (Pearce CB,

Gonzalez-Gonzalez JA, Garcia-Cantu DA, Gunn SR, Johnson CD)

190

Management and outcome of acute pancreatitis varies between centres. (Ashfaq K, Fee P, Moothoo D, Teague B, Wood L, Sanders K, Goel A, Sekhar R, Crighton I, Keating J)

191

Autoimmune pancreatitis: response to therapy in a UK series.

(Church NI, Pereira SP, Hatfield ARW, Webster GJM)

192

Biliary stenting versus palliative bypass surgery in locally advanced pancreatic adenocarcinoma. (Scott EN, Hoh C, Doucas H, Steward WP, Lloyd DM, Robertson GS, Dennison AR, Berry DP)

193

CT and endoscopic ultrasound (EUS) in the diagnosis and staging of pancreatic and periampullary malignancy. (Mansfield SD, Scott J, Oppong K, Richardson DL, Sen G,  Jaques BC, O’Suilleabhain CB, Manas DM, Charnley RM)

ENDOSCOPY

Poster Round will be conducted by ??????????????????????????

194

Does a two day on-site regional training programme improve colonoscopy service in a district general hospital? - a prospective study.

(Guruswamy R, Kejariwal D, Dron J, Williams M, Brett B)

195

Perceived value of teaching components used on colonoscopy training courses. (Thuraisingam AI, Anderson JT)

196

One-to-one  hands-on colonoscopy training course improves colonoscopy performance. (Thomas-Gibson S, Suzuki N, Vance M, Fraser C, Swain D, Schofield G, Saunders BP)

197

Endoscopic training and adverse outcomes (30 day post procedure mortality): an audit of 5715 procedures in a large teaching hospital. (Doshi B, Muckerjee K, Sagi S, Tedford M, Sharma G, Byrne A,

Brown L, Jones K, Bodger K, Sturgess R, Sarkar S)

198

A regional out of hours endoscopy service is an effective way of providing cover for GI bleeding across a number of different hospitals. (Fullard M, Benson M, Mendall M, Lim G, Clark S)

199

Endoscopists’ attitudes on the publication of “quality” data for endoscopic procedures. (Hearnshaw SA, Maddock HM, Nylander D, Prince MI)

200

Impact of endoscopist-performed trans-abdominal ultrasound on investigation of dyspepsia in direct-access endoscopy lists. (Levi S, Johnston BJ, Hossain F, Sekhar R)

201

Comparison of the efficacy, acceptability and safety of a new 2-litre PEG+E gut cleansing solution versus two established colon cleansing regimens. (Gruss H-J, Ell C, Bitoun A, Halphen M)

202

What happens to patients with iron deficiency anaemia (IDA) in whom no cause is found ? (Haine L, Pinder R, Rogers M (introduced by Duthie GS)

203

Antibiotic prophylaxis for infective endocarditis: impact of new British Cardiac Society guidelines. (Mehta G, East JE, Galletly N, Goodhand J, Thoua N, Smith GV, Bansi DS, Thillainayagam AV)

204

Predictors of re-intervention in endoscopic palliation of malignant gastroduodenal or colorectal obstruction with self-expandable metallic stents (SEMS). (Lynch PM, Lee EYT, Alrubaie A, Bailey AA, Kwan V, Loh SM, Williams SJ, Bourke MJ)

205

Does sending a video to patients lead to better informed consent? (Tawil A, Dew MJ)

206

Upper and lower GI-tract findings in patients with macrocytic and normocytic anaemia. (Powell N, McNair A)

207

Endoscopic investigation must be considered in patients with severe unexplained anaemia irrespective of MCV. (Connelly L, Burns B, Moncur PM, Saksena S)

208

Multifactorial anaemia in the elderly: well worth a look. (Mehta G, Ancock B, Galletly N, Goodhand J, Smith GV, Bansi DS,

Thillainayagam AV)

209

The changing face of OGD and colonoscopy in a tertiary referral centre – 11 Year audit of endoscopic practice. (Campbell S, Lombard M, Morris AI)

210

Changing practices in benzodiazepine sedation for endoscopy.

(Galletly NP, Goodhand J, Mehta G, Smith GV, Bansi DS, Thillainayagam AV)

211

Continuing the audit cycle: re-audit into colonoscopy sedation practice and sedation complications 1992-2004: 14,521 cases reviewed. (Sivayokan T, Leicester R, Poullis A)

212

Does body mass index influence pain following colonoscopy?

(de Silva PSA, Sayer JM)

213

Unsedated colonoscopy-for the many or for the few? (Sarkar A,

Smith KS, Johal SS, Donnelly MT)

214

Endoscopy in high risk cardiovascular patients. (Parkes G,

Fairclough P, Lindsay JO)

215

Cardiovascular assessment in patients following bowel preparation without intravenous fluid replacement: increased age does not mean decreased function. (Noblett SE, Horgan AF)

216

Conscious sedation and colonoscopy: are we neglecting patient's comfort for safety? (Hancock J, Nylander D, Tirou K, Zubair S,

Kasturi R, Connelly M, Gilbank B, Painter J, Bell GD)

217

Is sedation practice linked with adverse endoscopic outcome? an audit in response to the NCEPOD report. (Bowering K, McPhillips J, Vithanarchchi U, Mahindra P, Byne A, Sturgess R, Bodger K, Sarkar S)

218

A scoring system generated from patient consultation questionnaire to stratify risk of upper gastrointestinal cancer. (Al-Sarira A, Ballal M, Selvachandran S, Mckay J, London I, Cade D, Corless D)

219

An audit of mortality following PEG insertion and the impact of a nurse led pre-assessment service. (Riley R, Ahmed MM)

220

Upper gastrointestinal polyps :  why biopsy ? (Cherian S, Ahmed MM)

221

Value of 3D–EUS in staging and detailed accurate localisation of early oesophageal cancer prior to treatment. (Inglis S, Paterson-Brown S, Patel D, Plevris JN)

222

The value of repeating upper GI endoscopy after normal initial findings. (Boger CPC, Bridger S)

223

Wireless capsule oesophagoscopy (pillcam eso) compared to upper GI endoscopy in the detection of oesophageal varices. (Donnelly S, Campbell N, Forrest EH, Stanley AJ, Morris AJ)

224

Clinicopathological variables predict morbidity and early mortality following combined biliary stenting: a multivariate risk factor analysis. (Neal CP, Bools D, Thomasset SC, Sutton CD, Pattenden CJ,

Garcea G, Rees Y, Dennison AR, Berry DP, Robinson R)

225

Serial incremental stenting of symptomatic common bile duct strictures secondary to pancreatitis. (Lynch PM, Bailey AA, Lee EYT, Lee TLC, Williams SJ, Bourke MJ)

226

ERCP brush cytology or EUS-FNA for tissue diagnosis of obstructive jaundice secondary to biliary strictures. (Raine D, Ramakrishnan S, Wadehra V, Egan M, Charnley RM, Oppong K)

227

Endoscopic cystgastrostomy for pancreatic pseudocysts: an outcome assessment. (Nair S, Ramakrishnan S, Charnley RM, Oppong K)

228

Endoscopic palliation of concomitant malignant biliary stricture and gastroduodenal outflow obstruction. (Anderloni A, Montino F,

Del Piano M)

229

Comparison of diagnostic yield between biliary brushings & biliary biopsy: results of a pilot study. (Ali F, Richards D, Anagnostopoulos G, Zaitoun A, Griffiths P, Tofazzal N, Ragunath K, Aithal G)

230

Long-term outcome of patients with sphincter of Oddi dysfunction (SOD) after endoscopic sphincterotomy: a prospective study. (Pereira SP, Gillams A, Sgouros SN, Webster GJM, Hatfield ARW)

GASTRODUODENAL

Poster Round will be conducted by Professor J Atherton and Dr J Crabtree

231

Implementation of conventional and real-time PCR for routine diagnosis of Helicobacter pylori infection and antibiotic resistance. (Chisholm SA, Owen RJ (introduced by McColl KEL)

232

Helicobacter pylori induced upregulation of HB-EGF, but not COX-2 transcripts in gastric epithelial cells is via the epidermal growth factor receptor. (Tomtitchong P, Robinson PA, Crabtree JE)

233

Gastrin and members of the bcl-2 family regulate gastric epithelial apoptosis in vivo. (Przemeck S, Duckworth CA, Varro A, Pritchard DM)

234

Gastric histology, serological markers and age as predictors of gastric acid secretion in H pylori infected subjects. (Derakhshan MH,

El-Omar E, Oien K, Gillen D, Fyfe V, Crabtree JE, McColl KEL)

235

Pre-endoscopy discharge for upper gastro-intestinal haemorrhage: is it safe? (Warshow U, Hare N, Sanyal A, Murray, IA, Dalton HR)

236

How significant is a history of coffee-ground vomiting? (Gavin D,

Saraj O, Ng D)

237

Gastrointestinal symptoms in patients undergoing haemodialysis treatment. (Cano AE, Barnabas A, Neil AK, Nelson SR, Hartley ICR, Maxwell JD, Kang JY)

238

Comparison of zinc versus two bismuth based therapies after failure to eradicate Helicobacter pylori with standard triple treatment.

(Baburajan B, Bridger S, Doig L, Thompson RPH)

239

Evaluation of the efficacy of Helicobacter pylori eradication in a district general hospital. (Aljabiri MR, Arora G, Nugent S, O’Riordan D,

Cowan RE)

240

Prevalance of dyspepsia symptoms in the elderly: how they vary with sex and increasing age, and the effect on resource use. (Philpott SJ, Sundaram K, Mendall M)

241

H pylori, sex and the relation of extreme old age to dyspepsia.

(Philpott SJ, Sundaram K, Mendall M)

242

Effect of sibling number and birth order on Helicobacter pylori prevalence: a cross-sectional survey. (Ford AC, Bailey AG, Forman D, Axon ATR, Moayyedi P)

243

A ten-year natural history of gastro-oesophageal reflux disease.

(Ford AC, Bailey AG, Forman D, Axon ATR, Moayyedi P)

244

A cross-sectional survey of the relationship between gastro-oesophageal reflux disease and chronic cough. (Ford AC, Morice AH, Bailey AG, Forman D, Axon ATR, Moayyedi P)

PLENARY

Poster round will be conducted by Professor E Elias, Professor AI Morris, Dr J de Caestecker and Dr A Harris

125

Role of  protein kinase C in aldosterone-induced non-genomic inhibition of basolateral potassium channels in  human colonic crypts. (Linley JE, Bowley KA, Robins GG, Hunter M, Sandle GI)